全球医药市场中的环糊精 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球医药市场中的环糊精 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 页面
  • 桌子數: 540
  • 图号: 79

Global Cyclodextrins In Pharma Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 270.40 Million
Diagram Market Size (Forecast Year)
USD 370.06 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

全球医药市场中的环糊精,按类型(Β 环糊精、2-羟丙基-Β-环糊精、Α 环糊精、γ-环糊精、随机甲基化 Β-环糊精、磺丁基醚 Β-环糊精、2-羟丙基-Γ-环糊精)、结构(环糊精结合物、粘膜粘附药物载体、环糊精缔合物、两亲环糊精等)、性质(亲水性、疏水性)、形式(固体、液体)、应用(药物溶解度和溶出度、药物生物利用度、药物安全性、药物稳定性等)、治疗领域(疼痛管理、心血管疾病、行为障碍、癌症治疗、类风湿性关节炎、癫痫、尼曼匹克病) C 类(NPC)、其他)、分销渠道(直接招标、零售、其他)——2029 年行业趋势和预测

医药市场中的环糊精

市场分析和规模

近年来,预计在预测期内,环糊精在医药市场将快速增长。环糊精是一种淀粉基糖分子,具有亲脂性内部和亲水性外壳。由于其抗衰老特性,环糊精在化妆品制造商中需求量很大。它广泛用于制造化妆品和个人护理用品,如面霜、面膜和乳液等,预计将在未来几年推动市场扩张。同时,在世界范围内,提高整体免疫力的膳食补充剂越来越受欢迎,这可能会在预测期内推动市场扩张。

Data Bridge Market Research 分析称,2021 年制药市场中的环糊精价值为 2.704 亿美元,预计到 2029 年将达到 3.7006 亿美元,在 2022 年至 2029 年的预测期内复合年增长率为 4.00%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

环糊精是一种复杂的环状糖,由通过 α-1,4 糖苷键连接在一起的葡萄糖亚基大环组成。当淀粉被酶分解成简单分子时,就会形成环糊精。环糊精越来越多地用于制药和化学工业,作为药物输送中的溶剂成分。环糊精用于通过包封生物系统中的疏水性药物分子来增加药物的水溶性、稳定性和生物利用度。

报告范围和市场细分

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins, Others), Nature (Hydrophilic, Hydrophobic), Form (Solid, Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others), Therapeutics Area (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC), Others), Distribution Channel (Direct Tender, Retail Sales, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Cambrex Corporation (US), Cayman Chemical (US), Wellona Pharma (India), Wacker Chemie AG (Germany), Cyclolab (Hungary), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (US), Cyclo Therapeutics, Inc. (US), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (US), TCI Chemicals (India) Pvt. Ltd. (Japan)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Cyclodextrins in Pharma Market Dynamics

Drivers

  • Increasing consumption of dietary supplements

The rising consumption of dietary supplements is estimated to enhance the market's growth. Excipients such as cyclodextrin are utilized in pharmaceutical and nutraceutical formulations. As a result of the COVID-19 pandemic, doctors have prescribed a variety of antiviral medications to patients to help them fight the virus early on. The growing use of these medications has boosted cyclodextrin consumption, propelling market growth throughout the forecast period.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cyclodextrins in pharma market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cyclodextrins in pharma market. Additionally, the rapidly changing consumer attitudes toward health and the growing use of cyclodextrins in renal diseases will also result in the expansion of cyclodextrins in pharma market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cyclodextrins in pharma market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the cyclodextrins in pharma market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug distribution and development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cyclodextrins in pharma market. Additionally, strict regulatory policies coupled with the barriers to conducting diagnostics tests will restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cyclodextrins in pharma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclodextrins in pharma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cyclodextrins in pharma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cyclodextrins in Pharma Market

自 2019 年 12 月出现以来,COVID-19  病毒已传播到地球上几乎每个国家,促使世界卫生组织 (WHO) 宣布其为公共卫生紧急事件。COVID-19 是一种新型冠状病毒,被确定为肺炎病例的病原体。这种病毒迅速传播到世界各地,造成大量人员死亡。2020 年 3 月,世界卫生组织 (WHO) 将 COVID-19 列为全球大流行病,并建议采取严格措施防止该疾病传播。自那时起,这场大流行推迟了医疗保健部门的扩张并扰乱了供应链。此外,许多国家的政府实施了全国封锁,以阻止 COVID-19 的传播。同样,世界各地许多国家的医疗保健组织都难以继续其供应链活动。制药市场中的环糊精因供应链缓慢而受到阻碍。然而,现在 COVID-19 疫苗随时可用,许多当局正在努力确保不间断地供应救命药物和疫苗。因此,预计未来市场将会稳定下来。

全球环糊精在医药市场的应用范围

医药市场中的环糊精根据类型、结构、性质、形式、应用、治疗领域和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

类型

  • Β 环糊精
  • 2-羟丙基-β-环糊精
  • α-环糊精
  • γ-环糊精
  • 随机甲基化β-环糊精
  • 磺丁基醚β-环糊精
  • 2-羟丙基-γ-环糊精

结构

  • 环糊精结合物
  • 粘膜粘附药物载体
  • 环糊精缔合物
  • 两亲性环糊精
  • 其他的

自然

  • 亲水性
  • 疏水性

形式

  • 坚硬的
  • 液体

应用

  • 药物溶解度和溶解
  • 药物生物利用度
  • 药品安全
  • 药物稳定性
  • 其他的

治疗领域

  • 疼痛管理
  • 心血管疾病
  • 行为障碍
  • 癌症治疗
  • 类风湿关节炎
  • 癫痫
  • 尼曼匹克病 C 型(NPC)
  • 其他的

分销渠道

  • 直接招标
  • 零售销售
  • 其他的

医药市场中的环糊精区域分析/见解

对制药市场中的环糊精进行了分析,并按国家、类型、结构、性质、形式、应用、治疗领域和分销渠道提供了市场规模见解和趋势。

环糊精在制药市场报告中涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

由于北美地区新环糊精药物在药理学领域处于领先地位,北美在环糊精医药市场占据主导地位。此外,医疗支出的增加和疾病特异性治疗需求的增加将进一步推动该地区市场的增长速度。

由于亚太地区消费者对医药产品环糊精化合物的需求不断增长,预计该地区在 2022 年至 2029 年的预测期内将实现增长。此外,医疗基础设施的发展和政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医药市场竞争格局及环糊精份额分析

制药市场环糊精竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对制药市场环糊精的关注有关。

制药市场中环糊精的一些主要参与者是:

  • Cambrex 公司 (美国)
  • 开曼化学 (美国)
  • Wellona Pharma(印度)
  • 瓦克化学股份有限公司(德国)
  • Cyclolab(匈牙利)
  • 托科医药有限公司 (中国)
  • 罗盖特兄弟公司(法国)
  • Midas Pharma GmbH(德国)
  • Ligand Pharmaceuticals Incorporated(美国)
  • Cyclo Therapeutics, Inc.(美国)
  • 淄博千汇生物科技有限公司 (中国)
  • 西安德利生化工业股份有限公司 (中国)
  • 默克集团(德国)
  • Otto Chemie Pvt. Ltd.(印度)
  • VIO CHEMICALS(瑞士)
  • 阿什兰(美国)
  • TCI Chemicals (India) Pvt. Ltd.(日本)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 THERAPEUTIC AREAS LIFELINE CURVE

2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.1 DBMR MARKET POSITION GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 REGULATIONS

5.1 FDA

5.2 JAPAN

6 IMPACT OF COVID-19 ON GLOBAL CYCLODEXTRIN IN PHARMA MARKET

6.1 PRICE IMPACT

6.2 IMPACT ON DEMAND

6.3 IMPACT ON SUPPLY CHAIN

6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

6.5 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS

7.1.2 INCREASING DRUG STABILITY

7.1.3 USE OF CYCLODEXTRIN IN DRUG DELIVERY

7.1.4 LAUNCH OF FINISHED PRODUCTS OF CYCLODEXTRIN

7.1.5 RISING PREVALENCE OF CHRONIC DISEASES

7.2 RESTRAINTS

7.2.1 HIGH COSTS OF CYCLODEXTRIN

7.2.2 TOXICITY STUDIES OF CYCLODEXTRINS

7.3 OPPORTUNITIES

7.3.1 INCREASING RESEARCH OF CYCLODEXTRIN IN COVID-19 TREATMENT

7.3.2 RISING USE OF CYCLODEXTRIN IN RENAL DISEASES

7.3.3 RISING INVESTMENT ON RESEARCH ACTIVITIES

7.3.4 INCREASES AWARENESS ABOUT THE USE OF CYCLODEXTRIN IN PHARMA INDUSTRY

7.4 CHALLENGES

7.4.1 LIMITATION OF CYCLODEXTRIN IN OPTHALMIC USE

7.4.2 USE OF VARIOUS TECHNIQUES IN MANUFACTURING CYCLODEXTRIN

8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE

8.1 OVERVIEW

8.1.1 Β CYCLODEXTRIN

8.1.2 2-HYDROXYPROPYL-Β-CYCLODEXTRIN

8.1.3 Α CYCLODEXTRIN

8.1.4 Γ-CYCLODEXTRIN

8.1.5 RANDOMLY METHYLATED Β-CYCLODEXTRIN

8.1.6 SULFOBUTYLETHER Β-CYCLODEXTRIN

8.1.7 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN

9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE

9.1 OVERVIEW

9.2 CYCLODEXTRIN CONJUGATES

9.2.1 POLYMERS

9.2.2 NANOSPONGES

9.3 MUCOADHESIVE DRUG CARRIERS

9.3.1 POLYETHYLENE-GLYCOL

9.3.2 CHITOSAN

9.3.3 ALGINATE

9.4 CYCLODEXTRIN ASSOCIATES

9.4.1 POLYPSEUDOROTAXANES

9.4.2 POLYROTAXANES

9.5 AMPHIPHILIC CYCLODEXTRINS

9.5.1 POLYSUBSTITUTED

9.5.2 MONOSUBSTITUTED

9.6 OTHERS

10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM

10.1 OVERVIEW

10.2 SOLID

10.3 LIQUID

11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE

11.1 OVERVIEW

11.2 HYDROPHILIC

11.3 HYDROPHOBIC

12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 DRUG SOLUBILITY AND DISSOLUTION

12.3 DRUG BIOAVAILABILITY

12.4 DRUG SAFETY

12.5 DRUG STABILITY

12.6 OTHERS

13 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS

13.1 OVERVIEW

13.2 PAIN MANAGEMENT

13.3 CARDIOVASCULAR DISEASES

13.4 BEHAVIORAL DISORDER

13.5 CANCER THERAPY

13.6 RHEUMATOID ARTHRITIS

13.7 EPILEPSY

13.8 NIEMANN PICK DISEASE TYPE C (NPC)

13.9 OTHERS

14 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.4 OTHERS

15 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY GEOGRAPHY

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 EUROPE

15.3.1 GERMANY

15.3.2 FRANCE

15.3.3 U.K

15.3.4 ITALY

15.3.5 NETHERLANDS

15.3.6 SPAIN

15.3.7 RUSSIA

15.3.8 SWITZERLAND

15.3.9 BELGIUM

15.3.10 TURKEY

15.3.11 AUSTRIA

15.3.12 NORWAY

15.3.13 HUNGARY

15.3.14 LITHUANIA

15.3.15 IRELAND

15.3.16 POLAND

15.3.17 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 JAPAN

15.4.2 CHINA

15.4.3 INDIA

15.4.4 SOUTH KOREA

15.4.5 AUSTRALIA

15.4.6 SINGAPORE

15.4.7 MALAYSIA

15.4.8 THAILAND

15.4.9 INDONESIA

15.4.10 PHILIPPINES

15.4.11 VIETNAM

15.4.12 REST OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ARGENTINA

15.5.3 PERU

15.5.4 REST OF SOUTH AMERICA

15.6 MIDDLE EAST & AFRICA

15.6.1 SAUDI ARABIA

15.6.2 SOUTH AFRICA

15.6.3 UAE

15.6.4 ISRAEL

15.6.5 EGYPT

15.6.6 KUWAIT

15.6.7 REST OF MIDDLE EAST & AFRICA

16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT

18 COMPANY PROFILE

18.1 ROQUETTE FRÈRES

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 LIGAND PHARMACEUTICALS INCORPORATED

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 TECHNOLOGY PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 WACKER CHEMIE AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 MERCK KGAA

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 CYCLOLAB

18.5.1 COMPANY SNAPSHOT

18.5.2 PRODUCT PORTFOLIO

18.5.3 RECENT DEVELOPMENTS

18.6 CAMBREX CORPORATION

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENTS

18.7 CAYMAN CHEMICAL

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 CYCLO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.9 MIDAS PHARMA GMBH

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 TOCOPHARM CO. LIMITED

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 WELLONA PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 XI'AN DELI BIOCHEMICAL INDUSTRY CO.,LTD.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 ZIBO QIANHUI BIOLOGICAL TECHNOLOGY CO.,LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

LIST OF TABLES 

TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT

TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN

TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN

TABLE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)

TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 6 GLOBAL 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 7 GLOBAL Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 8 GLOBAL Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 9 GLOBAL RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 10 GLOBAL SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 11 GLOBAL 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)

TABLE 13 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 14 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 15 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 16 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 17 GLOBAL CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 18 GLOBAL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 19 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 20 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 21 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)

TABLE 23 GLOBAL SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 24 GLOBAL LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)

TABLE 26 GLOBAL HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 27 GLOBAL HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)

TABLE 29 GLOBAL DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 30 GLOBAL DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 31 GLOBAL DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 32 GLOBAL DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 33 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)

TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

TABLE 44 GLOBAL DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 45 GLOBAL RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 46 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2018-2027 (USD THOUSAND)

TABLE 48 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 49 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 50 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 51 NORTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 52 NORTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 53 NORTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 54 NORTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 56 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 57 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 58 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 59 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 60 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 61 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 62 U.S. CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 63 U.S. CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 64 U.S. MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 65 U.S. AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 66 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 67 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 68 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 69 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 70 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 71 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 72 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 73 CANADA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 74 CANADA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 75 CANADA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 76 CANADA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 77 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 78 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 79 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 80 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 81 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 82 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 83 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 84 MEXICO CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 85 MEXICO CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 86 MEXICO MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 87 MEXICO AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 88 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 89 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 90 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 91 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 92 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 93 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 94 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 95 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 96 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 97 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 98 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 99 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 100 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 101 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 102 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 103 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 104 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 105 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 106 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 107 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 108 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 109 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 110 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 111 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 112 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 113 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 114 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 115 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 116 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 117 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 118 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 119 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 120 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 121 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 122 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 123 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 124 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 125 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 126 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 127 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 128 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 129 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 130 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 131 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 132 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 133 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 134 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 135 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 136 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 137 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 138 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 139 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 140 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 141 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 142 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 143 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 144 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 145 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 146 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 147 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 148 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 149 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 150 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 151 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 152 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 153 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 154 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 155 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 156 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 157 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 158 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 159 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 160 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 161 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 162 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 163 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 164 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 165 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 166 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 167 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 168 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 169 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 170 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 171 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 172 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 173 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 174 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 175 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 176 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 177 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 178 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 179 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 180 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 181 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 182 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 183 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 184 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 185 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 186 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 187 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 188 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 189 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 190 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 191 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 192 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 193 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 194 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 195 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 196 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 197 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 198 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 199 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 200 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 201 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 202 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 203 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 204 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 205 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 206 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 207 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 208 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 209 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 210 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 211 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 212 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 213 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 214 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 215 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 216 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 217 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 218 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 219 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 220 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 221 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 222 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 223 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 224 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 225 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 226 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 227 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 228 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 229 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 230 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 231 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 232 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 233 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 234 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 235 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 236 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 237 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 238 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 239 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 240 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 241 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 242 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 243 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 244 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 245 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 246 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 247 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 248 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 249 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 250 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 251 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 252 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 253 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 254 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 255 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 256 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 257 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 258 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 259 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 260 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 261 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 262 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 263 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 264 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 265 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 266 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 267 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 268 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 269 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 270 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 271 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 272 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 273 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 274 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 275 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 276 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 277 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 278 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 279 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 280 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 281 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 282 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 283 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 284 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 285 ASIA-PACIFIC CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 286 ASIA-PACIFIC CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 287 ASIA-PACIFIC MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 288 ASIA-PACIFIC AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 289 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 290 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 291 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 292 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 293 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 294 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 295 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 296 JAPAN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 297 JAPAN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 298 JAPAN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 299 JAPAN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 300 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 301 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 302 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 303 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 304 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 305 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 306 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 307 CHINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 308 CHINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 309 CHINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 310 CHINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 311 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 312 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 313 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 314 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 315 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 316 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 317 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 318 INDIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 319 INDIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 320 INDIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 321 INDIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 322 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 323 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 324 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 325 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 326 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 327 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 328 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 329 SOUTH KOREA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 330 SOUTH KOREA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 331 SOUTH KOREA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 332 SOUTH KOREA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 333 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 334 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 335 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 336 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 337 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 338 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 339 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 340 AUSTRALIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 341 AUSTRALIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 342 AUSTRALIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 343 AUSTRALIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 344 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 345 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 346 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 347 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 348 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 349 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 350 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 351 SINGAPORE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 352 SINGAPORE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 353 SINGAPORE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 354 SINGAPORE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 355 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 356 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 357 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 358 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 359 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 360 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 361 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 362 MALAYSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 363 MALAYSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 364 MALAYSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 365 MALAYSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 366 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 367 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 368 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 369 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 370 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 371 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 372 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 373 THAILAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 374 THAILAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 375 THAILAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 376 THAILAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 377 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 378 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 379 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 380 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 381 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 382 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 383 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 384 INDONESIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 385 INDONESIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 386 INDONESIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 387 INDONESIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 388 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 389 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 390 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 391 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 392 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 393 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 394 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 395 PHILIPPINES CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 396 PHILIPPINES CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 397 PHILIPPINES MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 398 PHILIPPINES AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 399 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 400 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 401 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 402 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 403 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 404 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 405 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 406 VIETNAM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 407 VIETNAM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 408 VIETNAM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 409 VIETNAM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 410 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 411 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 412 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 413 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 414 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 415 REST OF ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 416 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 417 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 418 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 419 SOUTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 420 SOUTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 421 SOUTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 422 SOUTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 423 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 424 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 425 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 426 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 427 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 428 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 429 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 430 BRAZIL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 431 BRAZIL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 432 BRAZIL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 433 BRAZIL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 434 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 435 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 436 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 437 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 438 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 439 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 440 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 441 ARGENTINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 442 ARGENTINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 443 ARGENTINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 444 ARGENTINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 445 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 446 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 447 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 448 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 449 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 450 PERU CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 451 PERU CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 452 PERU CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 453 PERU CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 454 PERU MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 455 PERU AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 456 PERU CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 457 PERU CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 458 PERU CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 459 PERU CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 460 PERU CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 461 REST OF SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 462 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 463 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 464 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 465 MIDDLE EAST & AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 466 MIDDLE EAST & AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 467 MIDDLE EAST & AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 468 MIDDLE EAST & AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 469 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 470 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 471 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 472 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 473 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 474 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 475 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 476 SAUDI ARABIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 477 SAUDI ARABIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 478 SAUDI ARABIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 479 SAUDI ARABIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 480 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 481 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 482 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 483 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 484 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 485 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 486 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 487 SOUTH AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 488 SOUTH AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 489 SOUTH AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 490 SOUTH AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 491 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 492 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 493 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 494 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 495 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 496 UAE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 497 UAE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 498 UAE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 499 UAE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 500 UAE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 501 UAE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 502 UAE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 503 UAE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 504 UAE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 505 UAE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 506 UAE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 507 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 508 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 509 ISRAEL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 510 ISRAEL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 511 ISRAEL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 512 ISRAEL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 513 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 514 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 515 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 516 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 517 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 518 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 519 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 520 EGYPT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 521 EGYPT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 522 EGYPT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 523 EGYPT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 524 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 525 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 526 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 527 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 528 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 529 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 530 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 531 KUWAIT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 532 KUWAIT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 533 KUWAIT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 534 KUWAIT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 535 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 536 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 537 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 538 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 539 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 540 REST OF MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

 

图片列表

LIST OF FIGURES 

FIGURE 1 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION

FIGURE 2 GLOBAL CYCLODEXTRINS IN PHARMA MARKET : DATA TRIANGULATION

FIGURE 3 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DBMR MARKET POSITION GRID

FIGURE 10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 13 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS AND INCREASES DRUG STABILITY IS DRIVING THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 14 B CYCLODEXTRIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN 2020 & 2027

FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, PIPELINE ANALYSIS

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET

FIGURE 18 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019

FIGURE 19 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019-2027 (USD THOUSAND)

FIGURE 20 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 21 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019

FIGURE 23 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019-2027 (USD THOUSAND)

FIGURE 24 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, CAGR (2020-2027)

FIGURE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, LIFELINE CURVE

FIGURE 26 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019

FIGURE 27 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019-2027 (USD THOUSAND)

FIGURE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, CAGR (2020-2027)

FIGURE 29 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, LIFELINE CURVE

FIGURE 30 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019

FIGURE 31 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019-2027 (USD THOUSAND)

FIGURE 32 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, CAGR (2020-2027)

FIGURE 33 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, LIFELINE CURVE

FIGURE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019

FIGURE 35 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019-2027 (USD THOUSAND)

FIGURE 36 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, CAGR (2020-2027)

FIGURE 37 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 39 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)

FIGURE 40 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 41 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 42 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

FIGURE 44 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 45 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019)

FIGURE 48 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2020 & 2027)

FIGURE 49 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019 & 2027)

FIGURE 50 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 51 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 52 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 53 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 54 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 56 EUROPE CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 57 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 58 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 59 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 60 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 61 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 62 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 63 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 64 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 65 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 66 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 67 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 68 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 69 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 70 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 71 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 72 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 73 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 74 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 75 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 76 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 77 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 78 EUROPE CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 79 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKETMARKET: COMPANY SHARE 2019 (%)

 

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market value for Cyclodextrins in Pharma Market is expected USD 370.06 million by 2029.
The Cyclodextrins in Pharma Market is to grow at a CAGR of 4.00% during the forecast by 2029.
On the basis of application, the Cyclodextrins in Pharma Market is segmented into Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others.
The major players operating in the Cyclodextrins in Pharma Market are Cambrex Corporation (US), Cayman Chemical (US), Wellona Pharma (India), Wacker Chemie AG (Germany), Cyclolab (Hungary), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (US), Cyclo Therapeutics, Inc. (US), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (US), TCI Chemicals (India) Pvt. Ltd. (Japan).